- Home
- MNOV
MNOV
Medicinova Inc
as 08-28-2025 3:33pm EST
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 68.2M | IPO Year: | 2005 |
| Target Price: | $7.00 | AVG Volume (30 days): | 62.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.13 - $2.55 | Next Earning Date: | 08-14-2025 |
| Revenue: | $134,599 | Revenue Growth: | -86.54% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Medicinova Inc News
MNOV Breaking Stock News: Dive into MNOV Ticker-Specific Updates for Smart Investing
TipRanks
2 months ago
MediciNova price target lowered to $5 from $6 at B. Riley
Associated Press Finance
4 months ago
MediciNova: Q1 Earnings Snapshot
Simply Wall St.
4 months ago
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
GlobeNewswire
4 months ago
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
GlobeNewswire
5 months ago
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
Simply Wall St.
7 months ago
US Exchange Penny Stocks To Watch In January 2025
Simply Wall St.
8 months ago
US Penny Stocks To Watch In December 2024
Zacks Small Cap Research
9 months ago
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…
Compare MNOV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNOV Medicinova Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.